Furthermore, the potential of GCG modulation, GLP-1 receptor agonists, and immune-checkpoint inhibitor therapy in context of GCG expression of COADREAD can be investigated in a precision medicine approach to identify tumor subtypes and optimal therapies. Here, GLP1R is linked to neoplasm.